Stock Events

Stock Events

Amplia Therapeutics Limited 

$0.14
2
+$0+0% Wednesday 16:25

Statistics

Day High
0.14
Day Low
0.14
52W High
0.27
52W Low
0.03
Volume
10,000
Avg. Volume
11,156
Mkt Cap
71.83M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

1JunExpected
Q3 2022
Q1 2023
Q3 2023
Q1 2024
Q1 2025
Q3 2025
Next
-0.02
-0.01
-0.01
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-7.64MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INNMF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Array Technologies
ARRY
Mkt Cap1.12B
Array BioPharma specializes in the development of targeted cancer therapies, competing in the same therapeutic areas as Amplia.
TG Therapeutics
TGTX
Mkt Cap5.35B
TG Therapeutics focuses on B-cell malignancies and autoimmune diseases, competing in the broader oncology and therapeutic market like Amplia.
Puma Biotechnology
PBYI
Mkt Cap351.05M
Puma Biotechnology develops targeted treatments for various forms of cancer, competing in the oncology market with Amplia.
Kura Oncology
KURA
Mkt Cap760.52M
Kura Oncology focuses on the development of precision medicines for the treatment of cancer, directly competing with Amplia in the oncology field.
Incyte
INCY
Mkt Cap19.09B
Incyte Corporation specializes in oncology products, directly competing with Amplia in developing treatments for cancer-related conditions.

About

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Show more...
CEO
Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D.
Employees
1
Country
AU
ISIN
AU0000023822

Listings

AU
AU
ATX.AU
OTC Link
US
INNMF

0 Comments

Share your thoughts

FAQ

What is Amplia Therapeutics Limited stock price today?▼
The current price of INNMF is $0.14 USD — it has increased by +0% in the past 24 hours. Watch Amplia Therapeutics Limited stock price performance more closely on the chart.
What is Amplia Therapeutics Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Amplia Therapeutics Limited stocks are traded under the ticker INNMF.
What is Amplia Therapeutics Limited market cap?▼
Today Amplia Therapeutics Limited has the market capitalization of 71.83M
When is the next Amplia Therapeutics Limited earnings date?▼
Amplia Therapeutics Limited is going to release the next earnings report on June 01, 2026.
What were Amplia Therapeutics Limited earnings last quarter?▼
INNMF earnings for the last quarter are -0.01 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Amplia Therapeutics Limited revenue for the last year?▼
Amplia Therapeutics Limited revenue for the last year amounts to 0 USD.
What is Amplia Therapeutics Limited net income for the last year?▼
INNMF net income for the last year is -7.64M USD.
How many employees does Amplia Therapeutics Limited have?▼
As of April 11, 2026, the company has 1 employees.
In which sector is Amplia Therapeutics Limited located?▼
Amplia Therapeutics Limited operates in the Health Care sector.
When did Amplia Therapeutics Limited complete a stock split?▼
The last stock split for Amplia Therapeutics Limited was on May 03, 2018 with a ratio of 1:10.
Where is Amplia Therapeutics Limited headquartered?▼
Amplia Therapeutics Limited is headquartered in Melbourne, AU.